Analyzing Mirati Therapeutics (MRTX) and Sevion Therapeutics (SVON)
Mirati Therapeutics (NASDAQ: MRTX) and Sevion Therapeutics (OTCMKTS:SVON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.
This is a summary of current recommendations and price targets for Mirati Therapeutics and Sevion Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings and Valuation
This table compares Mirati Therapeutics and Sevion Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mirati Therapeutics||N/A||N/A||-$83.11 million||($3.11)||-8.70|
|Sevion Therapeutics||$80,000.00||209.85||-$5.79 million||($4.91)||-0.06|
Sevion Therapeutics has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Sevion Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Mirati Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Sevion Therapeutics has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
This table compares Mirati Therapeutics and Sevion Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
64.4% of Mirati Therapeutics shares are held by institutional investors. 5.1% of Mirati Therapeutics shares are held by company insiders. Comparatively, 7.7% of Sevion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Mirati Therapeutics beats Sevion Therapeutics on 6 of the 11 factors compared between the two stocks.
About Mirati Therapeutics
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
About Sevion Therapeutics
Eloxx Pharmaceuticals, Inc., formerly Sevion Therapeutics, Inc., is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.